2. Gene
  3. GCGR - glucagon receptor Gene

GCGR - glucagon receptor Gene

  • 基因
  • 蛋白
  • 疾病
  • 相关产品
  • 直系同源

中文名称：胰高血糖素受体

种属: Homo sapiens

同用名: GGR; GL-R; MVAH

基因 ID: 2642 | 基因类型: protein coding

关于 GCGR

Cytogenetic location: 17q25.3 Genomic coordinates (GRCh38): 17:81,804,150-81,814,008 (from NCBI)

This gene has 6 transcripts (splice variants), 1 gene allele, 184 orthologues, 42 paralogues and is associated with 2 phenotypes. Biased expression in liver (RPKM 10.3), kidney (RPKM 5.0) and 1 other tissue.

功能概要

该基因编码的蛋白质是胰高血糖素受体，对控制血糖水平很重要。该基因的缺陷是非胰岛素依赖型糖尿病 (NIDDM) 的一个原因。[RefSeq 提供，2010 年 1 月]

The protein encoded by this gene is a Glucagon Receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of non-insulin-dependent diabetes mellitus (NIDDM).[provided by RefSeq, Jan 2010]

GCGR 基因产物(4)

mRNA Protein Name
XM_006722277.2 XP_006722340.1 glucagon receptor isoform X1
NM_000160.5 NP_000151.1 glucagon receptor precursor
XM_011523539.2 XP_011521841.1 glucagon receptor isoform X3
XM_017024446.2 XP_016879935.1 glucagon receptor isoform X2
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables glucagon receptor activity IDA
IDA: 通过直接分析推断
9287038 GOA
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway IDA
IDA: 通过直接分析推断
28514451 GOA
involved in adenylate cyclase-modulating G protein-coupled receptor signaling pathway IMP
IMP: 通过突变表型推断
9287038 GOA
involved in cellular response to glucagon stimulus IDA
IDA: 通过直接分析推断
9287038 GOA
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in plasma membrane IDA
IDA: 通过直接分析推断
9287038 GOA
located in plasma membrane IMP
IMP: 通过突变表型推断
28514451 GOA
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

GCGR 蛋白结构

HRM

HRM: Hormone receptor domain (56 - 122)

7tm_2

7tm_2: 7 transmembrane receptor (Secretin family) (139 - 396)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 477 a.a.
蛋白主名 其他名称

glucagon receptor

重组 GCGR 蛋白

目录号 产品名 蛋白编号 纯度
HY-P700411 GCGR Protein, Human (HEK293, N-His, C-Myc) P47871 (A26-K136) ≥95%

关联疾病

疾病名称 别名
Endocrine Pancreas Disease

Disorder Of Endocrine Pancreas
Type 2 Diabetes Mellitus

Insulin Resistance

NIDDM

Diabetes Mellitus, Non-Insulin-Dependent

Type 2 Diabetes

T2D

Noninsulin-Dependent Diabetes Mellitus

Diabetes Mellitus, Type Ii

Maturity-Onset Diabetes

Insulin Resistance, Severe, Digenic

Diabetes Mellitus, Type 2

Diabetes Mellitus, Noninsulin-Dependent

Diabetes Mellitus, Noninsulin-Dependent, Association With

Diabetes Mellitus, Noninsulin-Dependent, Late Onset

Hypertension, Insulin Resistance-Related, Susceptibility To

Insulin Resistance, Susceptibility To

Non-Insulin-Dependent Diabetes Mellitus

Type Ii Diabetes Mellitus

Adult-Onset Diabetes Mellitus

Maturity-Onset Diabetes Mellitus

Diabetes Mellitus Type 2

Type Ii Diabetes

Type 2 Diabetes Mellitus, Susceptibility To

Diabetes, Type 2

Diabetes Mellitus, Noninsulin-Dependent, Susceptibility To

Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility To

Diabetes Mellitus, Type 2, Susceptibility To

Diabetes Mellitus, Noninsulin-Dependent, 2

Diabetes Mellitus, Type Ii, Susceptibility To

Hypertension, Insulin Resistance-Related

Adult-Onset Diabetes

Aodm

Diabetes Mellitus, Adult-Onset

Diabetes Mellitus Type Ii

Diabetes Mellitus Type 2, Susceptibility To

Diabetes, Type Ii, Susceptibility To

Diabetes Type 2

Diabetes Mellitus

Adult Onset Diabetes

Maturity Onset Diabetes

Nonketotic Diabetes

Non-Insulin Dependent Diabetes Mellitus

T2dm - [Type 2 Diabetes Mellitus]

Niddm - [Non Insulin Dependent Diabetes Mellitus]

Dm2

Dm Type Ii

Diabetic Type 2

Insulin Requiring Type 2 Diabetes

Noninsulin Dependent Diabetes

Non-Insulin-Dependent Diabetes Mellitus Without Complications

Diabetes Due To Insulin Secretory Defect

Diabetes Mellitus Due To Insulin Secretory Defect

Non-Insulin-Dependent Diabetes Of The Young

Senile Diabetes

Nonketotic Hyperglycaemia

Stable Diabetes
Pheochromocytoma

Pheochromocytoma, Susceptibility To

Phaeochromocytoma

Adrenal Gland Chromaffin Paraganglioma

Adrenal Gland Chromaffinoma

Adrenal Gland Paraganglioma

Adrenal Gland Pheochromocytoma

Chromaffin Paraganglioma Of The Adrenal Gland

Intraadrenal Paraganglioma

PCC

Chromaffin Cell Tumor

Medullary Chromaffinoma

Medullary Paraganglioma

Pheochromoblastoma

Pheochromocytomas

Chromaffin Cell Neoplasm

Pheochromocytoma, Malignant
Hyperglycemia
Hypoglycemia

Hypoglycaemia

Low Blood Sugar

Hypoglycaemia Nos

Spontaneous Hypoglycaemia

Nondiabetic Hypoglycaemia

Hypoglycaemic Disorder Nos

Hypoglycaemic Syndrome
Epiphyseal Chondrodysplasia, Miura Type

ECDM

Tall Stature-Scoliosis-Macrodactyly Of The Great Toes Syndrome

Miura Type Epiphyseal Chondrodysplasia

Tall Stature-Scoliosis-Macrodactyly Of The Halluces Syndrome

Tall Stature-Long Halluces-Multiple Extra-Epiphyses Syndrome

Chondrodysplasia, Epiphyseal, Miura Type
Body Mass Index Quantitative Trait Locus 11

OBESITY

Obesity, Susceptibility To

Leanness, Inherited

Obesity, Susceptibility To, Bmiq11

Obesity, Mild, Early-Onset

Obesity, Association With

Obesity, Early-Onset, Susceptibility To

Obesity, Severe

Obesity, Severe, And Type Ii Diabetes

Obesity, Late-Onset

BMIQ11

Obesity Bmiq11

Obesity, Early-Onset

Obesity , Susceptibility To

Simple Obesity Nos

Excess Fat

Obesity, Not Elsewhere Classified, Body Mass Index Not Elsewhere Classified

Adiposis
Hypertension, Essential

Essential Hypertension

Hypertension

High Blood Pressure

Hypertension, Essential, Susceptibility To

Hypertensive Disease

Primary Hypertension

EHT

Hypertension, Salt-Sensitive Essential, Susceptibility To

Hyperpiesia

Idiopathic Hypertension

Hypertensive Disorder

Hypertension, Essential, Susceptibility To, 3

Hypertension, Essential 3

Hypertension, Essential, Salt-Sensitive

Hypertension, Essential, Susceptibility To, 6

Hypertension, Essential 6

Hypertension, Salt-Sensitive Essential

Hypertension, Susceptibility To

Hypertension, Essential, Susceptibility To, 4

Hypertension, Essential 4

Hypertension, Essential, Susceptibility To, 2

Hypertension, Essential 2

Hypertension, Essential, Susceptibility To, 1

Hypertension, Essential 1

Hypertension, Essential, Susceptibility To, 5

Hypertension, Essential 5

Htn

Vascular Hypertensive Disorder

Systemic Primary Arterial Hypertension

Hbp - [High Blood Pressure]

Systemic Arterial Hypertensive Disorder

Elevated Blood Pressure

Arterial Hypertension Nos

Hypertension Nos

Benign Hypertension

Systemic Arterial Hypertension

Systemic Hypertension

Artery Htn

Benign Htn

Vascular Htn

Vascular Hypertension

Cholesterol Hypertension

Cholesterol Htn

Idiopathic Htn

Malignant Hypertension

Malignant Htn

Raised Blood Pressure

Cardiovascular Hypertension

Primary Htn - [Hypertension]

High Arterial Tension

High Blood Pressure Disorder

Ht - [Hypertension]

Htn - [Hypertension]

Hypertensive Vascular Disease

Hypertensive Vascular Degeneration
Diabetes Mellitus

Diabetes
Prediabetes Syndrome

Impaired Glucose Tolerance

Prediabetes

Prediabetic State

IGT

Igt - [Impaired Glucose Tolerance]

Impaired Glucose Tolerance With Unspecified Complication

Impaired Glucose Tolerance Without Complication

Abnormal Glucose Tolerance
Mahvash Disease

Gcgr-Related Hyperglucagonemia

MVAH

Alpha-Cell Hyperplasia With Glucagonemia

Nesidioblastosis, Alpha Cell Hyperplasia, Microglucagonoma, And Nonfunctioning Islet Cell Tumor

Nesidioblastosis Alpha Cell Hyperplasia Microglucagonoma And Nonfunctioning Islet Cell Tumor
疾病名称 别名
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

相关产品

Approval
生物活性分子 (10)
目录号 产品名 作用方式
纯度 是否罕见病
HY-114118 Semaglutide Agonist 99.84% 否
HY-13443 Exendin-4 Agonist 99.95% 是
HY-P0014 Liraglutide Agonist 99.85% 否
HY-P0082 Glucagon (1-29), bovine, human 99.84% 否
HY-114118A Semaglutide TFA Agonist 99.92% 否
HY-P0119 Lixisenatide Agonist 99.93% 否
HY-P0120 Dulaglutide Agonist 90.00% 否
HY-P0119A Lixisenatide acetate Agonist 99.65% 否
HY-114118B Semaglutide acetate Agonist 99.93% 否
HY-P3469 Dasiglucagon Agonist / 否
Clinical Phase
生物活性分子 (28)
目录号 产品名 作用方式
纯度 Phase
HY-13443A Exendin-4 acetate Agonist 99.91% Phase 4
HY-P3463 Beinaglutide 99.74% Phase 4
HY-P3506 Retatrutide Agonist 99.95% Phase 3
HY-112185 Orforglipron Agonist 99.80% Phase 3
HY-P3375 Mazdutide Agonist 99.74% Phase 3
HY-P3506A Retatrutide TFA Agonist 99.31% Phase 3
HY-P2221B Glepaglutide acetate Agonist 99.92% Phase 3
HY-P0165 Taspoglutide Agonist 99.51% Phase 3
HY-P3366 Ecnoglutide Agonist 98.61% Phase 3
HY-P2221 Glepaglutide Agonist / Phase 3
HY-112668B Retagliptin hydrochloride / Phase 3
HY-P3375A Mazdutide TFA Agonist / Phase 3
HY-P3506B Retatrutide acetate Agonist / Phase 3
HY-125824 Danuglipron Agonist 98.63% Phase 2
HY-P4146 Survodutide Agonist 99.83% Phase 2
HY-50663 MK 0893 Antagonist 99.86% Phase 2
HY-19904 Adomeglivant Antagonist 99.63% Phase 2
HY-P2231A Cotadutide acetate Agonist 98.88% Phase 2
HY-P3291 Dapiglutide Agonist 99.40% Phase 2
HY-12525 LGD-6972 Antagonist ≥98.0% Phase 2
HY-19947 PF-06291874 Antagonist 99.18% Phase 2
HY-P4146A Survodutide TFA Agonist 99.62% Phase 2
HY-P2231 Cotadutide Agonist 98.88% Phase 2
HY-P10018 Bamadutide Agonist 99.96% Phase 2
HY-P10019 Pegsebrenatide Agonist / Phase 2
HY-P3498 Elsiglutide Agonist / Phase 2
HY-P10031 SAR441255 Agonist / Phase 1
HY-19374 BAY-27-9955 Antagonist / Phase 1
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 Phase
HY-P99383 Volagidemab Antagonist 98.43% Phase 2
HY-P99357 Crotedumab Inhibitor 96.61% Phase 1
Pre-clinical Phase
生物活性分子 (122)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P0055 GLP-1(7-37) 99.82% 否
HY-P0054 GLP-1(7-36), amide acetate 99.36% 否
HY-121835 GLP-1R agonist 2 Agonist 99.94% 否
HY-103546 BETP Agonist 99.35% 否
HY-101116 GLP-1R Antagonist 1 Antagonist 99.84% 否
HY-P1141 GLP-1(9-36)amide Antagonist 99.78% 否
HY-P0055A GLP-1(7-37) acetate 99.63% 否
HY-P1024 GLP-2(1-33)(human) Agonist 98.73% 否
HY-153865 Lotiglipron Agonist 99.68% 否
HY-P0054B GLP-1(7-36), amide TFA 98.66% 否
HY-124622 NNC-0640 Modulator 98.43% 否
HY-P1144 Oxyntomodulin (bovine, porcine) Agonist 99.91% 否
HY-142162 LSN3318839 Modulator 99.81% 否
HY-129658A TT-OAD2 Agonist 99.77% 否
HY-P1023 VIP(6-28)(human, rat, porcine, bovine) Antagonist 99.69% 否
HY-103547 L-168049 Antagonist 99.93% 否
HY-P1348 GLP-1 moiety from Dulaglutide 99.59% 否
HY-N0630 Shanzhiside methyl ester Agonist 99.71% 否
HY-P1145A Glucagon-like peptide 1 (1-37), human TFA Agonist 98.09% 否
HY-P1160 Bay 55-9837 Agonist 99.08% 否
HY-P3101 GLP-1(28-36)amide 98.64% 否
HY-P2625 GLP-2(3-33) Agonist 99.82% 否
HY-114118F Semaglutide, FITC labeled Agonist 95.51% 否
HY-112679 GLP-1 receptor agonist 2 Agonist 98.70% 否
HY-141839 GLP-1R modulator C16 Modulator 99.60% 否
HY-P3102 GLP-1(32-36)amide 98.42% 否
HY-50159 Glucagon receptor antagonists-3 Antagonist 98.52% 否
HY-P1143A [Des-His1,Glu9]-Glucagon amide TFA Antagonist 99.62% 否
HY-116819A VU0453379 hydrochloride Modulator ≥99.0% 否
HY-141842 GLP-1R modulator L7-028 Modulator 98.77% 否
HY-50158 Glucagon receptor antagonists-2 Antagonist 99.23% 否
HY-141840 GLP-1R modulator C5 Modulator 99.60% 否
HY-P0014S1 Liraglutide-13C5,15N TFA Agonist 98.19% 否
HY-P0150 Glucagon (19-29), human Inhibitor 99.11% 否
HY-P10032A NN1177 TFA Agonist 98.66% 否
HY-144035 GLP-1R agonist 4 Agonist 99.77% 否
HY-148844 GCGR antagonist 2 Antagonist 99.76% 否
HY-112185A Orforglipron hemicalcium hydrate Agonist 99.48% 否
HY-50675 GRA Ex-25 Inhibitor 99.07% 否
HY-144034 GLP-1R agonist 3 Agonist 99.15% 否
HY-145412 GLP-1 receptor agonist 7 98.41% 否
HY-116854 NNC 92-1687 Antagonist 98.74% 否
HY-148212 GLP-1R agonist 17 Agonist 99.82% 否
HY-P1141A GLP-1(9-36)amide TFA Antagonist 98.00% 否
HY-116819 VU0453379 Modulator ≥98.0% 否
HY-P5815A GLP-1 (1-36) amide (human, rat) (TFA) 98.81% 否
HY-10036 Glucagon receptor antagonists-1 Antagonist 98.65% 否
HY-P10736A AMG133 peptide payload TFA Agonist / 否
HY-P3622 (Ser8)-GLP-1 (7-36) amide, human Agonist 99.10% 否
HY-P1228 HAEGTFT 98.81% 否
HY-124803 GPCR modulator-1 Modulator / 否
HY-119739 Skyrin Antagonist 97.0% 否
HY-P1225 {Val1}-Exendin-3/4 99.45% 否
HY-147622 GLP-1R agonist 9 Agonist / 否
HY-P10032 NN1177 Agonist / 否
HY-P1231 GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 99.03% 否
HY-P1226 HAEGTFTSD Agonist 98.48% 否
HY-P1227 SDV-Exendin-3/4 95.96% 否
HY-P0054A GLP-1(7-36), amide Agonist 99.31% 否
HY-P2497 Exendin (5-39) Antagonist 99.81% 否
HY-N2452 Cochinchinenin C Agonist / 否
HY-P1229 FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 98.01% 否
HY-P1223 Exendin-3/4 (59-86) 98.19% 否
HY-P1224 HAEGTFTSDVS 98.62% 否
HY-145458 GLP-1 receptor agonist 9 Agonist / 否
HY-138996 GLP-1 receptor agonist 8 Agonist / 否
HY-129658 TT-OAD2 free base Agonist / 否
HY-128781 Glucagon receptor antagonists-5 Antagonist / 否
HY-159696A ISIS 449884 sodium Inhibitor / 否
HY-P5815 GLP-1 (1-36) amide (human, rat) / 否
HY-P10722 Efpegerglucagon Agonist / 否
HY-153476 GIP/GLP-1 dual receptor agonist-1 Agonist / 否
HY-P3050 Helospectin II Inhibitor / 否
HY-144133 GLP-1R agonist 5 Agonist / 否
HY-P3539 Exendin-4 (3-39) / 否
HY-P3616 Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide / 否
HY-159696 ISIS 449884 Inhibitor / 否
HY-P5161 FC382K10W15 Agonist / 否
HY-P4843 Gastric Inhibitory Polypeptide (6-30) amide (human) / 否
HY-144134 GLP-1R agonist 6 Agonist / 否
HY-P4503 (D-His1)-Exenatide Control / 否
HY-144135 GLP-1R agonist 7 Agonist / 否
HY-129657 GLP-1 receptor agonist 4 Agonist / 否
HY-107129 MK-3577 Antagonist / 否
HY-129656 GLP-1 receptor agonist 3 Agonist / 否
HY-13443F Exendin 4, biotin labeled / 否
HY-P1143 [Des-His1,Glu9]-Glucagon amide Antagonist / 否
HY-P4672 (Met(O)27)-Glucagon (1-29) (human, rat, porcine) / 否
HY-144136 GLP-1R agonist 8 Agonist / 否
HY-P5578 A8SGLP-1 Agonist / 否
HY-P3621 Biotinyl-Glucagon (1-29), human, bovine, porcine / 否
HY-P0212A Neuropeptide Y, porcine TFA / 否
HY-P10341 ZP3022 Agonist / 否
HY-P4459 (Des-Gly2)-Exenatide Control / 否
HY-106559 Sorbinicate Inhibitor / 否
HY-P2625S1 GLP-2(3-33) (Leu-13C6,15N) TFA Agonist / 否
HY-P3608 [Des-His1,Glu9] Glucagon Antagonist / 否
HY-P3102A GLP-1(32-36)amide TFA / 否
HY-P10736 AMG133 peptide payload / 否
HY-P3101A GLP-1(28-36)amide TFA / 否
HY-P5074 GRPP (human) Agonist / 否
HY-P5578A A8SGLP-1 TFA Agonist / 否
HY-P3542 Des His1, Glu8 Exendin-4 Antagonist / 否
HY-128103 Glucagon receptor antagonists-7 Antagonist / 否
HY-P0211 [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) Antagonist / 否
HY-P3388 Utreglutide Agonist 98.42% 否
HY-P1160A Bay 55-9837 TFA / 否
HY-169707 GCGR antagonist 3 Antagonist / 否
HY-P10337 OXM-7 Agonist / 否
HY-P0082A Glucagon (1-29), bovine, human hydrochloride / 否
HY-P5161A FC382K10W15 TFA Agonist / 否
HY-144033 GLP-1R agonist 1 Agonist / 否
HY-P1144A Oxyntomodulin (bovine, porcine) (TFA) Agonist / 否
HY-P0212 Neuropeptide Y, porcine Agonist / 否
HY-P3617 Glucagon (22-29) Agonist / 否
HY-142162A (S,R)-LSN3318839 Control / 否
HY-125824A Danuglipron tromethamine Agonist / 否
HY-12525A LGD-6972 sodium Antagonist / 否
HY-12735 SCH 900822 Antagonist / 否
HY-118914 Glucagon receptor antagonist inactive control Control / 否
HY-P1543 Exendin-3 Antagonist 98.31% 否
HY-P1145 Glucagon-like peptide 1 (1-37), human Agonist / 否
抗体抑制剂 (1)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P990013 Gulgafafusp alfa Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Felis catus GCGR VGNC VGNC:62492
Bos taurus GCGR VGNC VGNC:29285
Canis familiaris GCGR VGNC VGNC:41144
Rattus norvegicus GCGR RGD RGD:2669
Macaca mulatta GCGR VGNC VGNC:72899
Mus musculus GCGR MGD MGI:99572
Others GCGR NCBI
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z